NCT05709106Completed
A Prospective Real World Study of Rimegepant in the Treatment of Migraine
Source: ClinicalTrials.gov · Last updated 5 Feb 2026
Brief summary (registry, in English)
The goal of this observational study is to test the effectiveness and safety of Rimegepant in the treatment of migraine patients in real world. The main questions it aims to answer are: * \[question 1\] the effectiveness and safety of Rimegepant in the acute treatment of migraine * \[question 2\] the effectiveness and safety of Rimegepant in the long-term treatment of migraine. 1. Participants will be asked to take Rimegepant when they need to treat or prevent a migraine attack. 2. Participants will be asked to record the efficacy data at 0.5, 1, 2, 24, 48h post dose and report any AE to evaluate the effectiveness and safety of Rimegepant in the acute treatment of migraine 3. Participants will be asked to track monthly migraine days and the use of Rimegepant, finish 2 PROs during the follow-ups, report any AE to evaluate the effectiveness and safety of Rimegepant in the long-term treatment of migraine.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 173 (actual)
- First submitted
- 13 Jan 2023
- Start date
- 11 Jan 2023
- Primary completion date
- 6 Oct 2024
- Lead sponsor
- Ruijin-Hainan Hospital Shanghai Jiao Tong University School Of Medicine
- Diseases
- Migraine
- NCT number
- NCT05709106
What you commit to
- Study type: Observational
- Participants enrolled: 173
- From 11 Jan 2023 to the primary completion date, 6 Oct 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- The patients with severe visual, hearing, language, intelligence, memory, and consciousness disorders, are unable to cooperate with the completion of the questionnaire and follow-up.
Other
- Pregnant patients
- Lactating female patients
- Patients who are highly dependent on medical care.
Who the study is looking for
- Subjects diagnosed as migraines (with or without aura) consistent with a diagnosis according to the International Classification of Headache Disorders, 3rd Edition, beta version
- Rimegepant is prescribed by the physician for the treatment of patients with migraine.
- Patients signed written informed consent.
- Male and Female subjects ≥ 18 years and older
- Patients is not participated in other concurrent interventional clinical studies.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Ruijin-Hainan Hospital Shanghai Jiao Tong University School of Medicine Coordinator of this site? Confirm its status | Boao | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.